TELETRADER News
4/21, 3:41 PM (Source: TeleTrader)
more TeleTrader news

J&J vaccine site halts production over FDA probe

The United States Food and Drug Administration (FDA) unveiled on Wednesday that Emergent BioSolutions, a proposed manufacturing facility for the Johnson & Johnson COVID-19 vaccine, will temporarily suspend new production while the FDA ensures that the vaccine site fulfills all the conditions for high-quality jab production.

The FDA added that vaccines already made will "undergo additional testing" before being distributed for use. The issues raised by the FDA are unrelated to the alleged ties between the J&J vaccine and an increased risk of blood clots, the statement underlined.

"We are doing everything we can to ensure that the COVID-19 vaccines that are given to the people of this nation have met the agency's high standards for quality, safety and effectiveness," the FDA concluded.

Breaking the News / BU